Novogen JV's ovarian cancer drug effective in vivo
26 March, 2014 by Dylan Bushell-EmblingCanTx, a JV between Novogen (ASX:NRT) and Yale University, said its lead drug candidate Trx-1 induced an anti-tumoural effect in a mouse model of ovarian cancer.
Prima adds three more experts to advisory board
26 March, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has chosen three gynaecological oncology experts to join its clinical advisory board as it prepares for a new trial of CVac in epithelial ovarian cancer.
Trialling a new enzyme inhibitor
26 March, 2014 by Susan WilliamsonThe persistently high blood glucose levels associated with diabetes can, over time, cause damage to blood vessels that result in so-called diabetes-related complications. Preventing or reducing diabetes-related complications in the kidney is the focus of some of the work currently underway at the Baker IDI.
Sirtex and Guerbet team for liver cancer studies
25 March, 2014 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has signed an agreement to evaluate using its SIR-Spheres microspheres in conjunction with Guerbet's Lipidol to treat a range of liver cancers.
Cogstate tests to be used in Alzheimer's study
25 March, 2014 by Dylan Bushell-EmblingCogstate (ASX:CGS) will supply cognition tests for a phase III trial involving using Eli Lilly's anti-amyloid drug Solanezumab to slow the onset of Alzheimer's disease.
Patrys preps for clinical trials of PAT-LM1
24 March, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) is gearing up to take its second anticancer antibody, PAT-LM1, to the clinic after the candidate showed promise in leukaemias and lymphomas.
Ascend cancer drug shows potential in CBCL
21 March, 2014 by Dylan Bushell-EmblingMore than 80% of patients with cutaneous B-cell lymphoma enrolled in a phase II trial of Ascend's in-licensed cancer drug ASN-002 demonstrated a complete or partial response to treatment.
STA gets TGA nod for Abraxane in pancreatic cancer
19 March, 2014 by Dylan Bushell-EmblingThe TGA has approved the use of Abraxane - a cancer drug licensed by Specialised Therapeutics Australia - in first-line treatment of metastatic pancreatic cancer.
Link between diabetes and pancreatic cancer
19 March, 2014A systematic review of independent studies has found an association between pancreatic cancer and diabetes.
Bionomics' renal cancer trial finds key subgroups
19 March, 2014 by Dylan Bushell-EmblingBionomics (ASX:BNO) has revealed that its BNC105 candidate improved PFS in subgroups of patients with advanced renal cancer during a phase II trial.
Virax to buy Pathway Oncology
19 March, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has arranged to buy Pathway Oncology, a company with an exclusive licence to a cancer drug candidate due to enter phase II trials in breast cancer and multiple myeloma.
Biomedical Research Victoria
18 March, 2014Melbourne's Bio21 Cluster has transitioned into Biomedical Research Victoria, a new statewide biomedical research group.
Imugene kicks off IND process for HER-Vaxx
18 March, 2014 by Dylan Bushell-EmblingImugene (ASX:IMU) has appointed Ground Zero Pharmaceuticals to help the company prepare its Investigational New Drug application with the US FDA for cancer vaccine HER-Vaxx.
Starpharma's VivaGel condoms approved in Japan
17 March, 2014 by Dylan Bushell-EmblingStarpharma's (ASX:SPL) marketing partner Okamoto Industries has won regulatory approval to market VivaGel-coated condoms in Japan.
Calzada appoints new chairman
17 March, 2014 by Dylan Bushell-EmblingCalzada's (ASX:CZD) newest director, David Williams, has been chosen to replace Roger Aston as board chairman.
